10-K: Pluri Inc. Reports Wider Loss Amid Strategic Diversification

Pluri Inc. reported a significant increase in net loss for fiscal year 2025, alongside a working capital deficit, despite revenue growth from its new CDMO and AgTech ventures.

Summary

• Pluri Inc. is a biotechnology company leveraging a proprietary 3D cell expansion platform for regenerative medicine, immunotherapy, food tech, AgTech, and CDMO services.
• Net loss for the fiscal year ended June 30, 2025, increased to $23.25 million, up from $21.34 million in 2024.
• Revenues grew significantly to $1.34 million in 2025 from $0.33 million in 2024, primarily from CDMO services and AgTech collaborations.
• The company reported a working capital deficit of $10.23 million as of June 30, 2025, compared to a surplus of $26.65 million in 2024.
• Cash balances (cash, cash equivalents, and bank deposits) decreased to $21.91 million in 2025 from $30.87 million in 2024.
• The NIAID contract for PLX-R18 cell therapy development was terminated for the government's convenience on April 15, 2025, after providing $2.3 million in funding.
• Pluri acquired approximately 79% of Kokomodo Ltd., an Israeli startup pioneering cell-cultured cacao, for $4.5 million in common shares.
• Ever After Foods, a cultivated meat joint venture, completed a $10 million private placement, with Pluri investing $1.25 million, and expanded its license to include fish and seafood.
• The company is in advanced discussions with the European Investment Bank (EIB) regarding restructuring the terms of a €20 million loan, due June 1, 2026.
• Pluri regained compliance with Nasdaq's listing requirements regarding market value of listed securities and Audit Committee composition.

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including a widening net loss, a substantial working capital deficit, and a 'going concern' warning from auditors. While strategic diversification into new verticals and some revenue growth are positive, the termination of a key contract and uncertainty around EIB loan restructuring highlight considerable operational and financial risks. The need for substantial additional capital and potential dilution further weighs on the outlook.

Positives

• Revenues increased significantly to $1.34 million in fiscal year 2025, up from $0.33 million in 2024, driven by CDMO services and AgTech collaborations.
• Launched PluriCDMO in January 2024, generating revenues from cell therapy manufacturing services.
• Established Coffeesai Ltd. in 2024, focused on cultivated, cell-cultured coffee, which has successfully demonstrated a proof-of-concept beverage.
• Acquired approximately 79% of Kokomodo Ltd. in April 2025, expanding into sustainable cell-cultured cacao production.
• Ever After Foods, the cultivated meat joint venture, secured a $10 million private placement, with Pluri investing $1.25 million, and expanded its technology license to include fish and seafood.
• Entered into strategic collaborations in AgTech with ICL Group Ltd. and a leading international agriculture corporation, including a $1 million POC agreement.
• Received new patent approvals from the Israel Patent Office and USPTO for 3D bioreactor technology and immune cell expansion, expanding the intellectual property portfolio to over 250 patents pending, allowed, and granted.
• Regained compliance with Nasdaq Listing Rule 5550(b)(2) regarding market value of listed securities and Nasdaq Listing Rule 5605(c)(2)(A) regarding Audit Committee composition.
• Received IIA funding for collaboration with Bar-Ilan University Research and Development Company Ltd. to develop placental-derived MAIT cells for solid tumors, with an initial budget of approximately $163,000.

Negatives

• Net loss increased to $23.25 million for the year ended June 30, 2025, compared to $21.34 million in 2024.
• Reported a working capital deficit of $10.23 million as of June 30, 2025, a significant decrease from a $26.65 million surplus in 2024.
• Cash, cash equivalents, and restricted cash decreased by $720,000, and total cash balances (including bank deposits) decreased from $30.87 million to $21.91 million.
• The $4.2 million contract with NIAID for PLX-R18 cell therapy development was terminated for the government's convenience on April 15, 2025, after receiving $2.3 million.
• Recurring operating losses and negative cash flow raise substantial doubt about the company's ability to continue as a going concern.
• Uncertainty regarding the outcome of advanced discussions with the EIB for restructuring the €20 million loan, which is due on June 1, 2026.
• Financial expenses, net, shifted from an income of $1.68 million in 2024 to an expense of $0.21 million in 2025, mainly due to Euro-USD exchange rate fluctuations on the EIB loan.
• Research and development, net, increased by 3% to $12.85 million, partially due to write-off provisions in clinical studies and increased subcontractor costs.

Risks

• History of losses and no significant revenues to date, with expectations of future losses and no significant or steady revenues in the immediate future.
• Need to raise additional capital, which may be costly, difficult to obtain, and could dilute shareholders' ownership interests.
• Independent registered public accounting firm included an explanatory paragraph relating to the company's ability to continue as a going concern.
• Potential claims by larger, better-funded competitors enforcing or invalidating intellectual property rights.
• Inherent risks in manufacturing product candidates, including meeting high regulatory standards, which could adversely affect operations.
• Inability to obtain and maintain intellectual property protection covering products and technology.
• Exposure to various global and local risks as an international business, including currency exchange rate fluctuations (NIS and Euro).
• Market prices of common shares are subject to fluctuation and volatility.
• Restrictions contained in the EIB Finance Agreement may limit strategic initiatives.
• Limitations related to grants received from the Israel Innovation Authority (IIA) may impact future plans and decisions.
• Significant shifts in political, economic, and military conditions in Israel and neighboring countries could adversely affect business.
• Difficulty for investors in the United States to enforce judgments against the company or its non-U.S. directors/officers.
• Cybersecurity incidents, other technology disruptions, potential risks associated with AI, or failure to comply with privacy laws could negatively impact business and reputation.
• Recent increasing global inflation could affect material purchases, increase costs, and impact product development.
• Limited operating history in FoodTech, AgTech, and CDMO, with prospects dependent on meeting several challenges.
• Risks related to the CDMO business, including contract termination, lack of market approval for products, and competitive industry pressures.
• Risks related to food-tech endeavors, including changes in consumer preferences and governmental regulations for cultivated meat.
• Unproven business and market potential in cultivated food and cell-based coffee technology, with limited insight into emerging trends.
• Lengthy and complex research and development process for cultivated meat manufacturing technologies.
• Failure to maintain compliance with Nasdaq listing requirements could harm liquidity and ability to raise capital.

Future Outlook

The company has an accumulated deficit of $443.06 million and does not anticipate generating significant revenues from product sales in the next twelve months, with near-term revenues unlikely to exceed operating costs. Additional liquidity is required to support commercialization and R&D activities. The ability to execute the business plan is dependent on obtaining sufficient additional capital, entering licensing/collaboration agreements, providing CDMO services, finalizing EIB loan restructuring, and securing other funding sources, including non-dilutive grants. Management estimates insufficient resources for at least twelve months from the financial statements' issuance date, raising substantial doubt about the company's ability to continue as a going concern.

Management Comments

• "We believe that the termination [of the NIAID contract] reflects broader federal budgetary and administrative adjustments that have affected various health-related agencies, including the NIH."
• "We believe that our MAIT cells, isolated from the human placenta, offer substantial potential benefits compared to conventional T cells."
• "We believe that Ever After Foods is poised to revolutionize the food industry and offer consumers a sustainable and delicious alternative to traditional meat."
• "We believe that our competitive positioning is derived from our technology platform capabilities and our innovative developments."
• "We believe that this platform provides meaningful advantages in scalability, cost-efficiency and product quality, positioning us to address critical challenges in cellular agriculture that competitors often face in achieving industrial-scale production."

Industry Context

Pluri Inc. operates in highly competitive and evolving sectors including regenerative medicine, immunotherapy, cultivated food (FoodTech), agricultural technology (AgTech), and Contract Development and Manufacturing Organization (CDMO). The regenerative medicine field is characterized by intense competition from global pharma, biotech, academic institutions, and governmental agencies. The cultivated food market is emerging but competitive, with both consumer-facing and B2B players. The AgTech industry is driven by biotechnology advancements and sustainability initiatives. Pluri aims to differentiate through its proprietary 3D cell expansion platform, in-house manufacturing, and diverse IP portfolio, seeking to address unmet needs and global challenges in these verticals.

Comparison to Industry Standards

• In regenerative medicine, Pluri faces competition from numerous allogeneic and autologous cell therapy companies, including those with 1,483 ongoing clinical trials globally, with 403 in solid tumors (ARM Report H1 2025).
• For allogeneic CAR-T therapy products for solid tumors, approximately 20 products are in clinical stages, with notable competitors including Adicet Bio (CD70-CAR gamma-delta T cells), Poseida (Allogenic MUC1-CAR Tscm cells), Fate (allogeneic MICA/B-CAR T cells), and MD Anderson (TROP2-CAR NK cells).
• In FoodTech, Ever After Foods competes with consumer-facing companies like Upside Foods, Believer Meats, and GOOD Meat, and B2B players such as Gelatex, Esco Aster, Ark Biotech, and GEA. Ever After Foods claims a unique proprietary technology optimized for natural cell growth, aiming for significantly lower cost and larger scale production compared to traditional approaches.
• In AgTech, competitors in plant cell culture for specialty ingredients include California Cultured, Inc. and Ayana Bio LLC, as well as established producers like DSM Firmenich AG and Givaudan International SA.
• For cell-cultured coffee, Coffeesai competes with California Cultured, Inc., Food Brewer AG, Another Food Pte. Ltd., and Atomo Foods, Inc., differentiating through advanced scale-up technology and bioprocessing expertise.
• For cell-cultured cacao, Kokomodo competes with Celleste Bio Ltd., California Cultured, Inc., and Food Brewer AG, leveraging the same 3D cell expansion platform for consistent, large-scale production.
• In CDMO services, PluriCDMO competes with large service providers like Lonza Group AG, AGC Biologics A/S, and Charles River Laboratories International, Inc., emphasizing its state-of-the-art manufacturing efficiency and capabilities for advanced cell therapy clinical trials.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings were reported in Item 3.

Related Party Transactions

• Acquisition of approximately 79% of Kokomodo Ltd. for $4.5 million in common shares from Chutzpah Holdings Limited and Plantae Bioscience Ltd., both controlled by Mr. Alexandre Weinstein, a director of the company.
• Mr. Alexandre Weinstein, a director, participated in a private placement offering in January 2025 through a wholly-owned company, acquiring common shares and warrants.

Stakeholder Impact

• Shareholders face significant dilution risk due to the ongoing need for capital raises and recent private placements.
• Shareholders are exposed to increased financial risk due to recurring losses, a working capital deficit, and the 'going concern' warning.
• Employees may experience uncertainty due to the company's financial condition and potential cost-containment measures.
• Customers and partners in CDMO, FoodTech, and AgTech may benefit from continued R&D and commercialization efforts, but face risks related to the company's financial stability and ability to deliver on long-term projects.
• Creditors, particularly the EIB, face uncertainty regarding the repayment of the €20 million loan, which is due soon and subject to restructuring discussions.

Next Steps

• Obtain sufficient additional capital to support commercialization and R&D activities.
• Finalize discussions with the European Investment Bank (EIB) regarding restructuring the terms and extending the maturity date of the €20 million loan.
• Enter into additional licensing or other commercial, partnerships, and collaboration agreements.
• Continue to provide CDMO services to clients and attract new clients.
• Seek other sources of funding, including non-dilutive grants.
• Advance development of MAIT cells for solid tumors, supported by IIA funding and collaboration with BIRAD.
• Optimize flavor and aroma profiles for cell-cultured coffee through bioprocess optimization and downstream refinement.
• Explore research and development collaborations for cell-cultured coffee with leading global coffee suppliers.
• Scale Kokomodo's cell-based cacao technology beyond proof-of-concept to industrial-scale production.

Key Dates

Recommendation

The company's financial position is highly precarious, evidenced by a substantial net loss of $23.25 million, a significant working capital deficit of $10.23 million, and an explicit 'going concern' warning from its independent auditors. While strategic diversification and some revenue growth are noted, these are insufficient to offset the severe liquidity issues and recurring operating losses. The termination of a key NIAID contract and the uncertainty surrounding the EIB loan restructuring further exacerbate financial instability. The high risk of significant shareholder dilution from future capital raises, coupled with geopolitical risks in Israel, makes the stock a 'strong sell' for seasoned investors.

Keywords

Biotechnology, Cell Therapy, Regenerative Medicine, Immunotherapy, Food Tech, Cultivated Meat, AgTech, Cell-Cultured Coffee, Cell-Cultured Cacao, CDMO, SEC Filing, 10-K, PLUR, Nasdaq, Israel Innovation Authority, European Investment Bank, PLX Cells, MAIT Cells, Intellectual Property